Statin safety: an assessment using an administrative claims database.
The large administrative databases of health plans contain information on drug-related medical adverse events (AE) and constitute an increasingly powerful tool for the assessment of drug safety. We conducted a retrospective observational study using an administrative managed care claims database covering 9 million members from diverse regions of the United States. Patients aged >or=18 years who received >or=2 prescriptions for lipid-lowering drugs between July 1, 2000 and December 1, 2004 were included in the study. Hospitalizations with diagnosis codes (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9]) related to muscle, kidney, and liver were determined for patients exposed to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), fibrates, extended-release niacin, cholesterol absorption inhibitors, or statin combination therapy. A total of 473,343 patients contributed 490,988 person-years of monotherapy and 11,624 person-years of combination dyslipidemia therapy. Rates of hospitalization due to AEs in patients on monotherapy with currently available statins were similar, whereas the incidence of hospitalization for muscle disorders increased 6.7-fold with cerivastatin therapy. Patients who received a lipid-lowering medication with a concomitant cytochrome P450 3A4 (CYP3A4) inhibitor had a 6-fold increased rate of muscle disorders, including rhabdomyolysis. Hypertension was associated with a 5-fold increase in both muscle and renal events, whereas patients with diabetes mellitus had a 2.5-fold increased risk of renal events. No hospitalized cases of the index AEs were observed in study subjects during the 6-month period before initiation of the lipid-lowering drug. Statin monotherapy as currently prescribed is generally well tolerated and safe.
HealthCore, Inc., Wilmington, Delaware 19801, USA. mcziraky@healthcore.com
Mark J
MJ
Cziraky
Vincent J
VJ
Willey
James M
JM
McKenney
Siddhesh A
SA
Kamat
Maxine D
MD
Fisher
John R
JR
Guyton
Terry A
TA
Jacobson
Michael H
MH
Davidson
D056486:Chemical and Drug Induced Liver Injury; D003324:Coronary Artery Disease / Q000453:epidemiology; D065607:Cytochrome P-450 Enzyme Inhibitors; D016208:Databases, Factual; D003920:Diabetes Mellitus / Q000453:epidemiology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D006973:Hypertension / Q000453:epidemiology; D007674:Kidney Diseases / Q000139:chemically induced / Q000453:epidemiology; D008107:Liver Diseases / Q000453:epidemiology; D008297:Male; D008329:Managed Care Programs; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced / Q000453:epidemiology; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors